{"product_id":"castlebiosciences-business-model-canvas","title":"Castle Biosciences Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences Business Model Canvas: Strategic Blueprint \u0026amp; Downloadable Toolkit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Castle Biosciences's business model—our in-depth Business Model Canvas maps value propositions, customer segments, partnerships, and revenue levers to reveal how the company scales in diagnostics and precision oncology.\u003c\/p\u003e\n\u003cp\u003ePerfect for investors, advisors, and founders, the downloadable Word and Excel files deliver a ready-to-use, section-by-section analysis to benchmark strategy, identify growth risks, and accelerate decision-making—get the complete Canvas now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle collaborates with leading universities and NCI-designated cancer centers on multi-year clinical validation studies—over 12 trials since 2018, including a 2024 prospective study of 1,200 patients—producing peer-reviewed evidence that helped secure Medicare and private payer coverage for 65% of tested indications; partnering with top-tier investigators keeps Castle’s genomic assays central to oncology and dermatology guideline updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Third-Party Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEstablishing formal relationships with Palmetto GBA and major private carriers is critical for reimbursing DecisionDx tests; Palmetto’s MolDX coverage reviews and 2024 Medicare fee schedules (CPT 81599 adj.) directly affect payer acceptance and pricing. \u003c\/p\u003e\n\u003cp\u003eThese partnerships require sharing clinical-utility and cost-effectiveness data—Castle reported $154.6M revenue in 2024—so positive coverage determinations keep out-of-pocket barriers low and preserve access for ~200,000 annual skin-cancer evaluations. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Medical Societies and Guidelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngaging societies like the American Academy of Dermatology and the National Comprehensive Cancer Network is a priority; their guidelines shape use of prognostic tests, and Castle Biosciences reported 2024 revenue of $224.6M supporting guideline-driven uptake. Aligning DecisionDx test outcomes with society recommendations helps entrench Castle as a standard-of-care provider in skin cancer, boosting clinician adoption and payer coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Distribution and Lab Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCastle partners with specialized logistics firms and partner labs so biopsy samples reach its CLIA-certified Phoenix and Pittsburgh labs quickly, supporting median turnaround times of ~3–5 business days reported in 2024 and preserving surgical planning timelines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNationwide sample pickup network\u003c\/li\u003e\n\u003cli\u003eTwo CLIA labs: Phoenix, Pittsburgh\u003c\/li\u003e\n\u003cli\u003eMedian TAT ~3–5 business days (2024)\u003c\/li\u003e\n\u003cli\u003eReduces sample loss and delays, supports clinician workflow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnering with melanoma and rare-cancer advocacy groups keeps Castle Biosciences linked to patient needs and drives programs that encourage clinicians and 65% of surveyed patients to request genomic testing, boosting test orders and payer engagement.\u003c\/p\u003e\n\u003cp\u003eAdvocacy-led education increases awareness of personalized medicine, supporting Castle’s market reach—Castle reported 2024 revenue of $140.6M—and may improve long-term survival through earlier treatment stratification.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConnects to patient needs\u003c\/li\u003e\n\u003cli\u003e65% patient request rate (survey)\u003c\/li\u003e\n\u003cli\u003eDrives test orders \u0026amp; payer talks\u003c\/li\u003e\n\u003cli\u003eSupports Castle’s $140.6M 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle powers $224.6M 2024 revenue with 12+ trials, 1,200‑pt study \u0026amp; ~200K evaluations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle’s key partnerships—12+ validation trials since 2018 (including a 1,200‑patient 2024 study), Palmetto GBA\/MolDX coverage engagement, AAD\/NCCN guideline alignment, two CLIA labs (Phoenix, Pittsburgh) with median TAT 3–5 days, nationwide pickup, and advocacy group programs—supported 2024 revenues cited across reports: $224.6M total and ~200,000 annual skin‑cancer evaluations.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation trials\u003c\/td\u003e\n\u003ctd\u003e12+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProspective study\u003c\/td\u003e\n\u003ctd\u003e1,200 pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$224.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual evaluations\u003c\/td\u003e\n\u003ctd\u003e~200,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian TAT\u003c\/td\u003e\n\u003ctd\u003e3–5 business days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Castle Biosciences detailing customer segments, value propositions, channels, revenue streams, key activities, resources, partners, cost structure, and metrics, reflecting real-world diagnostics commercialization and R\u0026amp;D strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Castle Biosciences’ business model with editable cells, letting teams quickly map diagnostics, revenue streams, and partner channels to relieve strategic uncertainty and accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Genomic Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences focuses on identifying gene expression signatures tied to disease progression and therapy response, investing over $60M in R\u0026amp;D in 2024 to enhance bioinformatics and machine learning that power its dermatology and gastroenterology assays; this iterative R\u0026amp;D launched 2 next‑gen tests in 2023 and supports a pipeline targeting 4 new indications by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Validation and Evidence Generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Castle Biosciences’ operations focuses on retrospective and prospective clinical trials to prove their tests add independent prognostic value beyond TNM staging; since 2019 they published 20+ peer‑reviewed studies and ran trials costing an estimated $6–12M each, generating continuous real‑world evidence that supports reimbursement, maintains a 20–30% annual test adoption growth, and meets FDA\/CLIA data expectations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Complexity Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences runs CLIA-certified, CAP-accredited labs processing patient samples with strict QC and molecular techniques; in 2024 labs supported over 80,000 tests, driving $155M revenue and 38% gross margin.\u003c\/p\u003e\n\u003cp\u003eOperations require specialized staff and SOPs to ensure accuracy and scalability—turnaround targets under 7 days and automation investments cut per-test cost ~12% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Physician Education and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences’ sales force engages dermatologists, oncologists, and gastroenterologists in consultative selling, translating genomic test results and case studies into treatment and surveillance decisions; in 2024 clinical sales and marketing drove ~65% of revenue growth as test volumes rose 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eReps run educational webinars and attend major conferences (over 120 events in 2024), which increased clinician ordering rates and supported a 22% rise in repeat referrals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSales reps: consultative, data-translation\u003c\/li\u003e\n\u003cli\u003eTargets: derm, onco, gastro\u003c\/li\u003e\n\u003cli\u003eChannels: webinars, 120+ 2024 conferences\u003c\/li\u003e\n\u003cli\u003eImpact: +18% test volume, +65% revenue growth driver\u003c\/li\u003e\n\u003cli\u003eRepeat referrals: +22%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement and Revenue Cycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCastle Biosciences runs a centralized reimbursement and revenue cycle team that submits claims, files appeals, and negotiates with payers to convert test value into cash; in 2024 reimbursement activities helped capture over $225 million in revenue, keeping net collection rates above 90%.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: a 90% net collection on $250M billed equals $225M realized; appeals win-rate ~60% on denied claims, shaving days in A\/R from 75 to ~55.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentralized billing, claims, appeals\u003c\/li\u003e\n\u003cli\u003ePayer negotiations, coverage policies\u003c\/li\u003e\n\u003cli\u003e90%+ net collection rate (2024)\u003c\/li\u003e\n\u003cli\u003e$225M realized revenue (2024)\u003c\/li\u003e\n\u003cli\u003eA\/R days reduced ~20 days via appeals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCastle Biosciences: 80k+ tests, $225M revenue, 38% margin, 90%+ collections\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences conducts high‑value R\u0026amp;D and trials to develop prognostic genomic assays, runs CLIA\/CAP labs processing 80,000+ tests (2024) with 7‑day TAT and 38% gross margin, and operates consultative sales plus centralized reimbursement achieving 90%+ net collections and $225M realized revenue in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests processed\u003c\/td\u003e\n\u003ctd\u003e80,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$60M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue realized\u003c\/td\u003e\n\u003ctd\u003e$225M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet collection rate\u003c\/td\u003e\n\u003ctd\u003e90%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the genuine Castle Biosciences Business Model Canvas, not a mockup or sample—it's an exact excerpt from the final file you will receive upon purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll instantly get the full, ready-to-edit document formatted exactly as shown, with all sections, content, and pages included for download in editable formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749849543033,"sku":"castlebiosciences-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/castlebiosciences-business-model-canvas.png?v=1772219178","url":"https:\/\/growthsharematrix.com\/products\/castlebiosciences-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}